Mitochondrial translation deficiency limits the cardiac benefit of ketogenic diet in early-onset cardiomyopathy
Аннотация
Mitochondrial cardiomyopathy is a devastating disorder with no effective treatment. Ketogenic diet (KD) has shown therapeutic benefit in some mitochondrial disease models but failed or caused harm in others, suggesting its efficacy depends on the underlying genetic defect. KD has ameliorated cardiomyopathy in models where the electron transport chain retains structural integrity, yet it has not been tested in a model with a primary defect in mitochondrial translation. We therefore examined KD in heart- and skeletal muscle-specific Dars2 knockout mice (hmKO), a model of fatal early-onset mitochondrial cardiomyopathy caused by loss of mitochondrial aspartyl-tRNA synthetase, which is essential for translation of all 13 mitochondrial DNA-encoded oxidative phosphorylation subunits. Male hmKO mice and wild type littermates received either a ketogenic or normal chow diet from weaning until the humane endpoint. KD induced a partial shift toward cardiac fatty acid metabolism and activated mitochondrial biogenesis signaling. However, these adaptations did not improve survival, cardiac hypertrophy, skeletal muscle atrophy, motor performance, respiratory chain complex abundance, enzyme activities, or cardiac ATP levels. KD reduced antioxidant gene expression, without increasing protein carbonylation, and amplified the mitokine response, with increased GDF15 and FGF21 in the heart and serum. These findings show that substrate availability alone cannot restore cardiac bioenergetics when mitochondrial translation capacity is severely impaired. Instead, mitochondrial translation machinery defines a critical boundary for metabolic interventions in mitochondrial cardiomyopathy. Our results argue that the therapeutic potential of KD in mitochondrial disease is mechanism-dependent and should not be generalized across genetically and bioenergetically distinct forms of mitochondrial cardiomyopathy.